Insertion of Intrauterine Contraception Clinical Trial
Official title:
Mepivacaine for Pain Relief at Insertion of Intrauterine Contraception
Use of long acting reversible contraception (LARC) such as implants or intrauterine
contraception (IUC) has been shown to reduce repeat abortions. LARCs have the advantage of
being independent of user error and are considered to be underused, especially among young
individuals where oral methods have high rates of user failure. IUC is often underused in
young or nulliparous women due to fear of pain at insertion.
10 ml of mepivacaine (10mg/ml) or 10ml of sodium hydrochloride will be injected into the
uterine cavity through a hydrosonography catheter before the tenaculum has been applied but
prior to sounding and to insertion of the IUC.
The investigators' hypothesis is that instillation of 10 ml (10mg/ml) mepivacaine though a
hydrosonography catheter prior to any instrument placement will provide more effective pain
relief than instillation of 10 ml placebo (sodium chloride 9mg/ml).
Primary objective: To evaluate the difference in pain score at the time of the insertion of
the IUC between treatment and control group.
Secondary objectives: To evaluate acceptability of the procedure.
n/a